| Trial ID: | L1650 |
| Source ID: | NCT02912494
|
| Associated Drug: |
Jr-131
|
| Title: |
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia
|
| Interventions: |
DRUG: JR-131|DRUG: Darbepoetin alfa
|
| Outcome Measures: |
Primary: Change from baseline in Hemoglobin level, 24 weeks |
|
| Sponsor/Collaborators: |
Sponsor: Kissei Pharmaceutical Co., Ltd. | Collaborators: JCR Pharmaceuticals Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: |Intervention Model: |Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose:
|
| Start Date: |
2016-09
|
| Completion Date: |
2017-09
|
| Results First Posted: |
|
| Last Update Posted: |
2019-04-02
|
| Locations: |
Multiple Locations, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT02912494
|
